Ticagrelor

Drug Class or Subclass

Cardiovascular medications

Anticoagulant / Antiplatelet agents

Generic

Ticagrelor

Brand Name

Brilinta

Import ID

143

Displaying 1 - 6 of 6

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Ritonavir Ticagrelor 1093	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding	Not studied		Not studied (may increase ticagrelor levels)	Avoid combination and use alternative antiplatelet agent
Darunavir Ticagrelor 964	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination and use alternative antiplatelet agent
Atazanavir Ticagrelor 848	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Use alternative agents
Nevirapine Ticagrelor 632	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Efavirenz Ticagrelor 484	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Elvitegravir Ticagrelor 212	Red: Avoid combination	Do not coadminister: Potential for increased levels of ticagrelor	Potential for increased risk of bleeding				Avoid combination and use alternative antiplatelet agent.

Subscribe to Ticagrelor